XENON PHARMACEUTICALS INC. (XENE) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Win.
37/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 6 wins, 6 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseXENE / S&P 3.80% / 15.20% |
LoseXENE / S&P -100.00% / 15.00% |
LoseXENE / S&P 33.52% / 50.40% |
| 2026-Q12/3 |
WinXENE / S&P 29.74% / -4.33% |
LoseXENE / S&P -100.00% / 11.30% |
WinXENE / S&P 45.51% / 27.70% |
| 2025-Q42/3 |
WinXENE / S&P 11.63% / 2.65% |
LoseXENE / S&P XENE unavailable / 9.00% |
WinXENE / S&P 44.37% / 13.40% |
| 2025-Q32/3 |
WinXENE / S&P 28.27% / 8.12% |
LoseXENE / S&P XENE unavailable / 4.61% |
WinXENE / S&P 37.94% / 13.45% |
| 2025-Q21/3 |
LoseXENE / S&P -6.71% / 10.94% |
LoseXENE / S&P XENE unavailable / 4.83% |
WinXENE / S&P 29.56% / 10.63% |
| 2025-Q11/3 |
LoseXENE / S&P -14.41% / -4.27% |
LoseXENE / S&P XENE unavailable / 4.98% |
WinXENE / S&P 19.19% / 10.57% |
| 2024-Q41/3 |
LoseXENE / S&P -0.43% / 2.41% |
LoseXENE / S&P XENE unavailable / 5.25% |
WinXENE / S&P 11.03% / 6.15% |
| 2024-Q31/3 |
LoseXENE / S&P 0.97% / 5.89% |
LoseXENE / S&P XENE unavailable / 5.89% |
WinXENE / S&P 6.42% / 6.11% |
| 2024-Q21/3 |
LoseXENE / S&P -9.43% / 4.28% |
LoseXENE / S&P XENE unavailable / 5.38% |
WinXENE / S&P 10.04% / 5.12% |
| 2024-Q11/3 |
LoseXENE / S&P -6.53% / 10.56% |
LoseXENE / S&P XENE unavailable / 5.71% |
WinXENE / S&P 16.81% / 5.59% |
| 2023-Q42/3 |
WinXENE / S&P 34.84% / 11.69% |
LoseXENE / S&P XENE unavailable / 6.81% |
WinXENE / S&P 33.33% / 7.78% |
| 2023-Q31/3 |
LoseXENE / S&P -11.27% / -3.27% |
LoseXENE / S&P XENE unavailable / 7.52% |
WinXENE / S&P 35.90% / -5.03% |
| 2023-Q21/3 |
LoseXENE / S&P 7.57% / 8.74% |
LoseXENE / S&P XENE unavailable / 9.50% |
WinXENE / S&P 43.10% / -8.57% |
| 2023-Q11/3 |
LoseXENE / S&P -9.23% / 7.50% |
LoseXENE / S&P XENE unavailable / 10.77% |
WinXENE / S&P 36.47% / -15.69% |
| 2022-Q41/3 |
WinXENE / S&P 9.22% / 7.56% |
LoseXENE / S&P -48.83% / 11.88% |
LoseXENE / S&P XENE unavailable / -17.99% |
| 2022-Q31/3 |
WinXENE / S&P 18.67% / -4.88% |
LoseXENE / S&P -33.65% / 13.47% |
LoseXENE / S&P XENE unavailable / -1.41% |
| 2022-Q22/3 |
WinXENE / S&P -0.49% / -16.10% |
WinXENE / S&P 15.77% / 13.71% |
LoseXENE / S&P XENE unavailable / 11.04% |
| 2022-Q11/3 |
WinXENE / S&P -2.14% / -4.60% |
LoseXENE / S&P -22.42% / 15.97% |
LoseXENE / S&P XENE unavailable / 42.23% |
| 2021-Q41/3 |
WinXENE / S&P 104.45% / 11.03% |
LoseXENE / S&P -42.68% / 15.00% |
LoseXENE / S&P XENE unavailable / 96.40% |
| 2021-Q30/3 |
LoseXENE / S&P -17.94% / 0.58% |
LoseXENE / S&P -34.59% / 10.77% |
LoseXENE / S&P XENE unavailable / 69.42% |
| 2021-Q20/3 |
LoseXENE / S&P 4.02% / 8.55% |
LoseXENE / S&P -33.02% / 6.58% |
LoseXENE / S&P XENE unavailable / 51.81% |
| 2021-Q11/3 |
WinXENE / S&P 16.38% / 6.17% |
LoseXENE / S&P XENE unavailable / -1.06% |
LoseXENE / S&P XENE unavailable / 7.39% |
| 2020-Q41/3 |
WinXENE / S&P 38.93% / 12.15% |
LoseXENE / S&P XENE unavailable / -3.72% |
LoseXENE / S&P XENE unavailable / -33.42% |
| 2020-Q30/3 |
LoseXENE / S&P -11.72% / 8.93% |
LoseXENE / S&P XENE unavailable / -2.04% |
LoseXENE / S&P XENE unavailable / -27.10% |
| 2020-Q20/3 |
LoseXENE / S&P 10.58% / 20.54% |
LoseXENE / S&P XENE unavailable / -0.46% |
LoseXENE / S&P XENE unavailable / -27.11% |
| 2020-Q11/3 |
WinXENE / S&P -13.50% / -19.60% |
LoseXENE / S&P XENE unavailable / 3.47% |
LoseXENE / S&P XENE unavailable / -14.75% |
| 2019-Q41/3 |
WinXENE / S&P 45.50% / 9.07% |
LoseXENE / S&P XENE unavailable / 5.36% |
LoseXENE / S&P XENE unavailable / 2.99% |
| 2019-Q30/3 |
LoseXENE / S&P -8.62% / 1.70% |
LoseXENE / S&P XENE unavailable / 5.02% |
LoseXENE / S&P XENE unavailable / 0.21% |
| 2019-Q21/3 |
LoseXENE / S&P -2.95% / 4.30% |
LoseXENE / S&P XENE unavailable / 6.64% |
WinXENE / S&P 11.04% / 8.65% |
| 2019-Q12/3 |
WinXENE / S&P 61.01% / 13.65% |
LoseXENE / S&P XENE unavailable / 8.12% |
WinXENE / S&P 19.33% / 14.29% |
| 2018-Q40/3 |
LoseXENE / S&P -52.20% / -13.52% |
LoseXENE / S&P XENE unavailable / 9.05% |
LoseXENE / S&P -8.14% / 18.23% |
| 2018-Q31/3 |
WinXENE / S&P 43.48% / 7.71% |
LoseXENE / S&P XENE unavailable / 10.21% |
LoseXENE / S&P 9.43% / 19.06% |
| 2018-Q21/3 |
WinXENE / S&P 87.76% / 3.43% |
LoseXENE / S&P XENE unavailable / 9.03% |
LoseXENE / S&P -7.78% / 14.46% |
| 2018-Q11/3 |
WinXENE / S&P 73.45% / -0.76% |
LoseXENE / S&P XENE unavailable / 7.68% |
LoseXENE / S&P -10.71% / 12.46% |
| 2017-Q41/3 |
LoseXENE / S&P -4.24% / 6.64% |
LoseXENE / S&P -82.75% / 7.03% |
WinXENE / S&P 16.22% / 13.82% |
| 2017-Q30/3 |
LoseXENE / S&P -6.35% / 4.48% |
LoseXENE / S&P -85.58% / 5.68% |
LoseXENE / S&P 11.19% / 17.57% |
| 2017-Q21/3 |
LoseXENE / S&P -21.25% / 3.09% |
LoseXENE / S&P -90.39% / 4.83% |
WinXENE / S&P 40.34% / 17.74% |
| 2017-Q11/3 |
LoseXENE / S&P -48.05% / 6.07% |
LoseXENE / S&P -89.99% / 3.67% |
WinXENE / S&P 100.00% / 13.32% |
| 2016-Q40/3 |
LoseXENE / S&P -4.94% / 3.82% |
LoseXENE / S&P -88.43% / 2.09% |
LoseXENE / S&P XENE unavailable / 7.05% |
| 2016-Q31/3 |
WinXENE / S&P 37.29% / 3.85% |
LoseXENE / S&P -72.99% / 0.20% |
LoseXENE / S&P XENE unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | XENE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 59.98% | 20.78% |
| Annualized return | 59.98% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | XENE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 241.21% | 83.14% |
| Annualized return | 27.82% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | XENE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 677.04% | 319.30% |
| Annualized return | 22.76% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |